Imugene (ASX:IMU) - Managing Director & CEO, Leslie Chong
Managing Director & CEO, Leslie Chong
Source: Imugene
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Imugene (IMU) records an income of more than $5.34 million for the half-year ending December 31, 2021, up from the $4.11 million in the prior corresponding period
  • The company posted a loss of $14.8 million, up from the previous $6.04 million, due to the significant increase in clinical trial and research activities undertaken
  • In November, Imugene entered a supply agreement with Merck Darmstadt and Pfizer to evaluate the safety and efficacy of its HER-Vaxx immunotherapy with chemotherapy
  • The company also used the half to recruit patients for its study of PD1-Vaxx in patients with non-small cell lung cancer
  • IMU shares steady at 23.5 cents

Imugene (IMU) has recorded income of $5.34 million for the half year ended December 31, 2021, up from the $4.11 million in the prior corresponding period.

The company posted a net loss for the six-month period of $14.8 million, up from a loss of about $6 million previously, largely due to the significant increase in clinical trial and research activities undertaken.

As a result of its successful share placement, share purchase plan and exercise of options during the latest reported half year, Imugene holds cash reserves of $118.4 million.

Operations

HER-Vaxx study

In November, Imugene entered a clinical trial supply agreement with Merck KGaA, Darmstadt and Pfizer to evaluate the safety and efficacy of its HER-Vaxx immunotherapy in combination with chemotherapy.

HER-Vaxx is designed to treat tumours that over-express the HER-2/neu receptor such as breast, lung, gastric, ovarian and pancreatic cancers.

The study’s primary endpoint is pathologic complete response and secondary endpoints include safety and biomarker evaluation.

Japan patent

In September, Imugene received a notice of grant from the Japanese Patent Office for HER-Vaxx.

The patent is titled “A vaccine Composition and Uses Thereof” and protects the method of composition and method of use of HER-Vaxx until 2036.

A patent was then granted in China under the same title and same terms as Japan.

PD1-Vaxx

Imugene used the half to recruit patients for its first-in-human, phase one, multi-centre, dose escalation study of PD1-Vaxx in patients with non-small cell lung cancer.

The primary goal is to determine the safety and optimal dose of PD1-Vaxx with patients either receiving 10, 50 or 100 micrograms.

PD1-Vaxx was designed to treat tumours such as lung cancer by producing an anti-cancer effect.

Clinical results indicate that it is showing early signs of an immune response in patients with antibodies related to PD1-Vaxx evident in assays.

IMU shares were steady at 23.5 cents at 1:29 pm AEDT.

imu by the numbers
More From The Market Online
HotCopper Daily Market Trends Graphic

Wednesday’s HotCopper trends, Bounty Oil & Gas, Nuix, Gorilla Gold Mines and other daily topics

With more than 600k average monthly users on the HotCopper forums, each and every discussion can move markets.
HotCopper Daily Market Trends Graphic

Tuesday’s HotCopper trends, Mayne Pharma Group, ION Video, Larvotto Resources and other daily topics

With more than 600k average monthly users on the HotCopper forums, each and every discussion can…

Mamba Exploration set for an early start to diamond drilling at Copper Hills

Mamba Exploration is set to kick off diamond drilling ahead of schedule at the Copper Hills…

Hamelin Gold expands Day Dawn gold footprint with high-grade hits in WA

Hamelin Gold has obtained further significant assay results from an RC drill program at the Day…